IN2014KN01075A - - Google Patents
Info
- Publication number
- IN2014KN01075A IN2014KN01075A IN1075KON2014A IN2014KN01075A IN 2014KN01075 A IN2014KN01075 A IN 2014KN01075A IN 1075KON2014 A IN1075KON2014 A IN 1075KON2014A IN 2014KN01075 A IN2014KN01075 A IN 2014KN01075A
- Authority
- IN
- India
- Prior art keywords
- compounds
- muscarinic
- receptor
- 16this
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161632813P | 2011-11-18 | 2011-11-18 | |
PCT/GB2012/052857 WO2013072705A1 (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014KN01075A true IN2014KN01075A (de) | 2015-10-09 |
Family
ID=47278335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1075KON2014 IN2014KN01075A (de) | 2011-11-18 | 2012-11-16 |
Country Status (17)
Country | Link |
---|---|
US (6) | US9187451B2 (de) |
EP (1) | EP2780015B1 (de) |
JP (2) | JP6083818B2 (de) |
CN (2) | CN106831541B (de) |
AU (3) | AU2012338581B2 (de) |
BR (1) | BR112014012056B1 (de) |
CA (1) | CA2856076C (de) |
DK (1) | DK2780015T3 (de) |
ES (1) | ES2619829T3 (de) |
GB (1) | GB2511685A (de) |
HK (1) | HK1201737A1 (de) |
HU (1) | HUE033114T2 (de) |
IN (1) | IN2014KN01075A (de) |
PL (1) | PL2780015T3 (de) |
PT (1) | PT2780015T (de) |
SG (1) | SG11201402405QA (de) |
WO (1) | WO2013072705A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2856076C (en) | 2011-11-18 | 2020-02-25 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
WO2014045031A1 (en) | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
GB2519470A (en) * | 2013-09-18 | 2015-04-22 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic M1 receptor agonists |
JP6479029B2 (ja) | 2014-02-06 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | ムスカリンm1受容体アゴニストとしての二環式アザ化合物 |
GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
CN108226319A (zh) * | 2016-12-22 | 2018-06-29 | 亚宝药业集团股份有限公司 | 一种检测卡巴拉汀贴剂中光学异构体的方法 |
TW201922758A (zh) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | 烯胺及烯胺的非鏡像選擇性還原 |
JP6691928B2 (ja) * | 2018-02-07 | 2020-05-13 | 株式会社ジンズホールディングス | アイウエアセット及び信号処理ユニット |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
CN113121495A (zh) * | 2020-01-10 | 2021-07-16 | 深圳市九明药业有限公司 | 一种地氯雷他定的制备方法 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56110674A (en) | 1980-01-24 | 1981-09-01 | Janssen Pharmaceutica Nv | Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative |
US4369184A (en) | 1980-01-24 | 1983-01-18 | Janssen Pharmaceutica N.V. | 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives |
US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
US5446051A (en) | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
WO1996013262A1 (en) | 1994-10-27 | 1996-05-09 | Merck & Co., Inc. | Muscarine antagonists |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
AU7478496A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine antagonists |
US5854245A (en) * | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US6664258B1 (en) | 1996-08-26 | 2003-12-16 | Pfizer Inc | Spirocyclic dopamine receptor subtype ligands |
EP0998285A4 (de) | 1997-06-18 | 2003-01-08 | Merck & Co Inc | ANTAGONISTEN DES ALPHA 1a ADRENERISCHEN REZEPTORS |
GB9715892D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
AU2307999A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
WO1999032489A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
WO1999032486A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
AU2095099A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists |
CZ286152B6 (cs) | 1998-03-13 | 2000-01-12 | Miroslav Ing. Csc. Vlček | Transparentní a semitransparentní difrakční prvky |
KR20010043032A (ko) * | 1998-04-28 | 2001-05-25 | 도모따께 다께시 | 1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체 |
US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
MXPA01011116A (es) | 1999-05-04 | 2002-06-04 | Schering Corp | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado. |
ES2246233T3 (es) | 1999-05-04 | 2006-02-16 | Schering Corporation | Derivados de piperidina utiles como antagonistas de ccr5. |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
JP2003529546A (ja) | 1999-09-13 | 2003-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | システインプロテアーゼの可逆的インヒビターとして有益な新規スピロ複素環化合物 |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
ATE275141T1 (de) | 1999-10-13 | 2004-09-15 | Banyu Pharma Co Ltd | Substituierte imidazolin-derivate |
US7163938B2 (en) * | 2000-11-28 | 2007-01-16 | Eli Lilly And Company | Substituted carboxamides |
US7164024B2 (en) | 2001-04-20 | 2007-01-16 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
JP2005505506A (ja) | 2001-06-12 | 2005-02-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用な大環状分子 |
WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
GB0128378D0 (en) | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
IL162616A0 (en) | 2001-12-28 | 2005-11-20 | Acadia Pharm Inc | Tetrahydroquinoline analogues as muscarinic agonists |
US7256186B2 (en) | 2002-02-06 | 2007-08-14 | Schering Corporation | Gamma secretase inhibitors |
US20040171614A1 (en) | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
WO2003082847A1 (fr) * | 2002-03-28 | 2003-10-09 | Tanabe Seiyaku Co., Ltd. | Derive de benzofurane |
EP1552842A1 (de) | 2002-06-07 | 2005-07-13 | Kyowa Hakko Kogyo Co., Ltd. | Bizyklische pyrimidin-derivate |
WO2004014853A1 (en) | 2002-07-31 | 2004-02-19 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
SI1551835T1 (sl) | 2002-09-30 | 2007-06-30 | Neurosearch As | Novi 1,4-diazabicikloalkanski derivati, njihova priprava in uporaba |
MXPA05005425A (es) | 2002-11-22 | 2005-11-23 | Japan Tobacco Inc | Heterociclos que contienen nitrogeno, biciclicos, fusionados. |
WO2004050024A2 (en) | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
WO2004069828A1 (ja) | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | ピペリジン化合物およびその医薬用途 |
JP4324791B2 (ja) * | 2003-07-17 | 2009-09-02 | アステラス製薬株式会社 | 2−アシルアミノチアゾール誘導体又はその塩 |
US20070078120A1 (en) | 2003-10-21 | 2007-04-05 | Hitoshi Ban | Novel piperidine derivative |
CA2554465A1 (en) | 2004-02-05 | 2005-08-25 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
JP2007522160A (ja) | 2004-02-10 | 2007-08-09 | エフ.ホフマン−ラ ロシュ アーゲー | ケモカインccr5受容体モジュレーター |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
WO2006058294A2 (en) | 2004-11-29 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
EP1863490A2 (de) | 2005-03-28 | 2007-12-12 | Vertex Pharmaceuticals Incorporated | Muskarinische modulatoren |
US8329694B2 (en) | 2005-06-24 | 2012-12-11 | Toyama Chemical Co., Ltd. | Quinoxalinones as antibacterial composition |
JP2009521483A (ja) * | 2005-12-22 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
CN101389630A (zh) | 2005-12-29 | 2009-03-18 | 艾博特公司 | 蛋白激酶抑制剂 |
AU2007221220A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
RU2008137593A (ru) | 2006-02-22 | 2010-03-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы мускариновых рецепторов |
EP2051712A2 (de) | 2006-08-15 | 2009-04-29 | Vertex Pharmceuticals Incorporated | Modulatoren muskarinischer rezeptoren |
WO2008077597A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors |
WO2008117229A1 (en) | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
US20090221567A1 (en) * | 2008-02-28 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177 |
JP5564033B2 (ja) | 2008-03-27 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規インヒビターとしてのアザ−ビシクロヘキシル置換インドリルアルキルアミノ誘導体 |
WO2010049146A1 (en) | 2008-10-29 | 2010-05-06 | Grünenthal GmbH | Substituted spiroamines |
EA020548B1 (ru) * | 2008-12-19 | 2014-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл |
NZ595432A (en) | 2009-04-17 | 2013-12-20 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
US20130197027A1 (en) | 2010-03-10 | 2013-08-01 | Craig Lindsley | Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same |
WO2011133750A1 (en) | 2010-04-22 | 2011-10-27 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
EP2563127A4 (de) | 2010-04-27 | 2013-11-06 | Merck Sharp & Dohme | Prolylcarboxypeptidase-hemmer |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
CN102918031A (zh) | 2010-05-28 | 2013-02-06 | 通用电气健康护理有限公司 | 放射标记的化合物及其方法 |
KR20130099970A (ko) | 2010-09-17 | 2013-09-06 | 어레이 바이오파마 인크. | Gpr119 조절제로서의 피페리디닐-치환된 락탐류 |
EP2685828A4 (de) | 2011-03-17 | 2014-08-13 | Merck Sharp & Dohme | Substituierte 3-azabicyclo-[3,1,0-]hexan-derivate als ccr2-antagonisten |
JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
CA2856076C (en) * | 2011-11-18 | 2020-02-25 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
WO2014045031A1 (en) | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
ES2694299T3 (es) | 2013-02-07 | 2018-12-19 | Heptares Therapeutics Limited | Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4 |
JP6479029B2 (ja) | 2014-02-06 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | ムスカリンm1受容体アゴニストとしての二環式アザ化合物 |
GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
ES2734734T3 (es) | 2015-02-13 | 2019-12-11 | Suven Life Sciences Ltd | Compuestos de amida como agonistas del receptor 5-HT4 |
GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
GB201709652D0 (en) | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
TW201922758A (zh) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | 烯胺及烯胺的非鏡像選擇性還原 |
GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202103211D0 (en) | 2021-03-08 | 2021-04-21 | Heptares Therapeutics Ltd | Pharmaceutical compounds for use in therapy |
-
2012
- 2012-11-16 CA CA2856076A patent/CA2856076C/en active Active
- 2012-11-16 PT PT127947513T patent/PT2780015T/pt unknown
- 2012-11-16 GB GB1410398.0A patent/GB2511685A/en not_active Withdrawn
- 2012-11-16 ES ES12794751.3T patent/ES2619829T3/es active Active
- 2012-11-16 US US14/358,984 patent/US9187451B2/en active Active
- 2012-11-16 JP JP2014541757A patent/JP6083818B2/ja active Active
- 2012-11-16 DK DK12794751.3T patent/DK2780015T3/en active
- 2012-11-16 PL PL12794751T patent/PL2780015T3/pl unknown
- 2012-11-16 CN CN201710078042.0A patent/CN106831541B/zh active Active
- 2012-11-16 SG SG11201402405QA patent/SG11201402405QA/en unknown
- 2012-11-16 CN CN201280066372.3A patent/CN104039321B/zh active Active
- 2012-11-16 WO PCT/GB2012/052857 patent/WO2013072705A1/en active Application Filing
- 2012-11-16 HU HUE12794751A patent/HUE033114T2/en unknown
- 2012-11-16 IN IN1075KON2014 patent/IN2014KN01075A/en unknown
- 2012-11-16 EP EP12794751.3A patent/EP2780015B1/de active Active
- 2012-11-16 AU AU2012338581A patent/AU2012338581B2/en active Active
- 2012-11-16 BR BR112014012056-0A patent/BR112014012056B1/pt active IP Right Grant
-
2015
- 2015-03-06 HK HK15102310.2A patent/HK1201737A1/xx unknown
- 2015-11-13 US US14/941,328 patent/US9573929B2/en active Active
-
2017
- 2017-01-19 JP JP2017007283A patent/JP6404374B2/ja active Active
- 2017-02-17 US US15/436,224 patent/US9907805B2/en active Active
- 2017-03-06 AU AU2017201505A patent/AU2017201505B2/en active Active
-
2018
- 2018-02-01 US US15/886,249 patent/US10413553B2/en active Active
- 2018-09-28 AU AU2018236871A patent/AU2018236871B2/en active Active
-
2019
- 2019-09-04 US US16/560,529 patent/US10973832B2/en active Active
-
2021
- 2021-04-09 US US17/226,523 patent/US11793817B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014KN01075A (de) | ||
CA2883210C (en) | Bicyclic aza compounds as muscarinic m1 receptor agonists | |
MX2020010674A (es) | Agonistas del receptor muscarinico. | |
MX2013004329A (es) | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. | |
MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
EP2582676A4 (de) | Positive allosterische tetrahydrochinolin-amid-m1-rezeptormodulatoren | |
MX2020001236A (es) | Compuestos aza biciclicos como agonistas del receptor muscarinico m1. | |
MX2013011922A (es) | Compuestos de benceno substituido. | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
UA115558C2 (uk) | Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань | |
IN2014MN00988A (de) | ||
IN2015DN01119A (de) | ||
MY160075A (en) | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
IN2014CN02273A (de) | ||
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
IN2014MN00697A (de) | ||
PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
IN2013DN02555A (de) | ||
MX342459B (es) | 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3. | |
IN2015DN02109A (de) | ||
IN2014DN03010A (de) |